Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
iBio, Inc. logo — AI-Powered Precision Antibody Therapeutics

iBio, Inc.

AI-Powered Precision Antibody Therapeutics

Founded 2008 United States San Diego, United States 50 employees Post Ipo Equity Total: $53.14M Biotechnology, Robotics

General Information

Company Name iBio, Inc.
Founded Year 2008
Location United States San Diego, United States +2
Employees 50
Industries Biotechnology, Robotics
Funding Stage Post Ipo Equity
Social

Get notified when iBio, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About iBio, Inc.

iBio, Inc. is a biotechnology startup founded in 2008, based in the United States, with a mission to develop safer and more effective immunotherapies for challenging cancers through their Discovery Platform. The company's slogan "AI-Powered Precision Antibody Therapeutics" highlights their use of artificial intelligence to guide drug discovery, making therapeutic development smarter, more precise, and faster. With a focus on hard-to-drug targets, iBio has $15.00M in Post-IPO Equity investment as of 26 March 2024 from investors including Ikarian Capital, Lynx1 Capital Management, and ADAR1 Capital Management. iBio's approach addresses the essential challenge in developing antibody drugs, which traditionally involves a high degree of randomness and time-consuming, costly methods. The company's nine immuno-oncology candidates in the pipeline aim to target solid tumors, glioblastoma, and head and neck cancers. By utilizing their Discovery Platform, iBio is poised to revolutionize the precision and efficiency of therapeutic development. This approach is expected to yield a higher success rate in bringing potentially life-saving drugs to market, thereby challenging the status quo in drug discovery and development.

Taxonomy: AI-powered drug discovery, Precision medicine, Immunotherapy, Antibody therapeutics, Biopharmaceuticals, Cancer treatment, Artificial intelligence in drug development, Monoclonal antibodies, Biologics production, Green plant transient gene expression, Bioprocessing technology, Drug target identification, Immuno-oncology, Biosimilar products, Pandemic disease response

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 3
Investor
•••• •••• 		26 Mar 2024
Post-IPO Equity •••••• - 06 Dec 2022
Post-IPO Debt •••••• 1 •••• •••• 01 Nov 2021
Post-IPO Equity •••••• - 10 Feb 2016
Post-IPO Equity •••••• - 13 Nov 2010

View All 6 Funding Rounds

iBio, Inc. Alternatives & Competitors

iBio, Inc. vs
Antikor Biopharma Ltd
Antikor Biopharma Ltd United Kingdom

Innovating in and developing the next generation of smaller-format ADCs for cancer therapy and beyon...

11 employees
Biotechnology, Health Care
Compare iBio, Inc. vs Antikor Biopharma Ltd
iBio, Inc. vs
Kuano
Kuano United Kingdom

Providing innovative quantum and AI solutions for drug discovery and design.

Seed
19 employees
AI, Biotechnology
Compare iBio, Inc. vs Kuano
iBio, Inc. vs
Phenomic
Phenomic Canada

Phenomic’s mission is to raise the survival curve for the hardest to treat solid tumors (e.g., color...

Seed
14 employees
AI, Biotechnology
Compare iBio, Inc. vs Phenomic

FAQ About iBio, Inc.

AI-Powered Precision Antibody Therapeutics
iBio, Inc. was founded in 2008.
iBio, Inc. is headquartered in San Diego, United States.
iBio, Inc. operates in the following industries: Biotechnology, Robotics.
iBio, Inc. has approximately 50 employees.
iBio, Inc. has completed 6 funding rounds, raising a total of $53.14M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to iBio, Inc. include Antikor Biopharma Ltd, Kuano, Phenomic, Atomwise, Design Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iBio, Inc. and Antikor Biopharma Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors iBio, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy